Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Gemcitabine Pharmacogenomics: Deoxycytidine Kinase and Cytidylate Kinase Gene Resequencing and Functional Genomics

Neslihan Aygun Kocabas, Pinar Aksoy, Linda L. Pelleymounter, Irene Moon, Jeong-Seon Ryu, Judith A. Gilbert, Oreste Ezequel Salavaggione, Bruce W. Eckloff, Eric D. Wieben, Vivien Yee, Richard M. Weinshilboum and Matthew M. Ames
Drug Metabolism and Disposition September 2008, 36 (9) 1951-1959; DOI: https://doi.org/10.1124/dmd.108.020925
Neslihan Aygun Kocabas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pinar Aksoy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Linda L. Pelleymounter
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Irene Moon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeong-Seon Ryu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Judith A. Gilbert
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Oreste Ezequel Salavaggione
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bruce W. Eckloff
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric D. Wieben
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vivien Yee
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard M. Weinshilboum
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew M. Ames
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Gemcitabine and other cytidine antimetabolites require metabolic activation by phosphorylation. Deoxycytidine kinase (DCK) and cytidine monophosphate kinase (CMPK) catalyze these reactions. We have applied a genotype-to-phenotype strategy to study DCK and CMPK pharmacogenomics. Specifically, we resequenced DCK and CMPK using 240 DNA samples, 60 each from African-American, Caucasian-American, Han Chinese-American, and Mexican-American subjects. We observed 28 DCK polymorphisms and 28 polymorphisms in CMPK, 33 of which were novel. Expression in COS-1 cells showed that variant allozyme enzyme activities ranged from 32 to 105% of the wild type (WT) for DCK and from 78 to 112% of WT for CMPK—with no significant differences in apparent Km values for either enzyme except for a DCK Val24/Ser122 double variant allozyme. Relative levels of DCK and CMPK immunoreactive protein in the COS-1 cells paralleled relative levels of enzyme activity and were significantly correlated for DCK (Rp = 0.89, P = 0.0004) but not for CMPK (Rp = 0.82, P = 0.095). The results of an analysis of DCK and CMPK structural models were compatible with the observed functional consequences of sequence alterations in variant allozymes. We also confirmed that the CMPK protein expressed in COS-1 cells and in a rabbit reticulocyte lysate was 196 rather than 228 amino acids in length. In summary, we determined common sequence variations in DCK and CMPK and systematically evaluated their functional implications. These gene sequence differences may contribute to variations in the metabolic activation of gemcitabine and other cytidine antimetabolites.

Footnotes

  • This work was supported in part by National Institutes of Health Grants R01 GM28157, R01 GM35720, R01 CA132780, and U01 GM61388 (The Pharmacogenetics Research Network), by a PhRMA Foundation “Center of Excellence in Clinical Pharmacology” Award, and by a grant from the Commonwealth Foundation for Cancer Research. The gene resequencing data described in this article have been deposited in the NIH-funded database PharmGKB with submission numbers PS207098 and PS207100.

  • N.A.K. and P.A. contributed equally to this work.

  • Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.

  • doi:10.1124/dmd.108.020925.

  • ABBREVIATIONS: dFdC, 2′-deoxy-2′,2′-difluorocytidine, gemcitabine; AraC, cytosine arabinoside; DCK, deoxycytidine kinase; CMPK, cytidine monophosphate kinase; dFdCDP, gemcitabine diphosphate; dFdCTP, gemcitabine triphosphate; AA, African-American; CA, Caucasian-American; HCA, Han Chinese-American; MA, Mexican-American; SNP, single nucleotide polymorphism; cSNP, coding single nucleotide polymorphism; PCR, polymerase chain reaction; 5′-FR, 5′-flanking region; MAF, minor allele frequency; ORF, open reading frame; WT, wild type; kb, kilobase(s).

  • ↵ Embedded Image The online version of this article (available at http://dmd.aspetjournals.org) contains supplemental material.

  • ↵1 Current affiliation: University of Gazi, Faculty of Pharmacy, Department of Toxicology, Ankara, Turkey.

  • ↵2 On leave of absence from Istanbul University, Pharmacy Faculty, Department of Biochemistry, Istanbul, Turkey.

  • ↵3 Current affiliation: Inha University Hospital, Incheon, South Korea.

  • ↵4 Current affiliation: Roswell Park Cancer Institute, Buffalo, New York.

    • Received February 12, 2008.
    • Accepted June 11, 2008.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 36 (9)
Drug Metabolism and Disposition
Vol. 36, Issue 9
1 Sep 2008
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Gemcitabine Pharmacogenomics: Deoxycytidine Kinase and Cytidylate Kinase Gene Resequencing and Functional Genomics
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Gemcitabine Pharmacogenomics: Deoxycytidine Kinase and Cytidylate Kinase Gene Resequencing and Functional Genomics

Neslihan Aygun Kocabas, Pinar Aksoy, Linda L. Pelleymounter, Irene Moon, Jeong-Seon Ryu, Judith A. Gilbert, Oreste Ezequel Salavaggione, Bruce W. Eckloff, Eric D. Wieben, Vivien Yee, Richard M. Weinshilboum and Matthew M. Ames
Drug Metabolism and Disposition September 1, 2008, 36 (9) 1951-1959; DOI: https://doi.org/10.1124/dmd.108.020925

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Gemcitabine Pharmacogenomics: Deoxycytidine Kinase and Cytidylate Kinase Gene Resequencing and Functional Genomics

Neslihan Aygun Kocabas, Pinar Aksoy, Linda L. Pelleymounter, Irene Moon, Jeong-Seon Ryu, Judith A. Gilbert, Oreste Ezequel Salavaggione, Bruce W. Eckloff, Eric D. Wieben, Vivien Yee, Richard M. Weinshilboum and Matthew M. Ames
Drug Metabolism and Disposition September 1, 2008, 36 (9) 1951-1959; DOI: https://doi.org/10.1124/dmd.108.020925
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • A PBPK model for CBD in adults and children
  • Olanzapine Glucuronidation in Humanized Mice
  • rs2242480 Regulates the Expression of CYP3A4 and CYP3A5
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics